Adaptive Biotechnologies and Collaborators to Present Eight Studies at the 2015 American Society of Clinical Oncology Annual Meeting Demonstrating the Relevance of Monitoring Immune Receptors as a New Class of Biomarkers

May 29, 2015, 09:00 ET from Adaptive Biotechnologies

SEATTLE, May 29, 2015 /PRNewswire/ -- Adaptive Biotechnologies, the leader in next generation sequencing (NGS) to profile T- and B-cell receptors of the adaptive immune system, and its collaborators will present data demonstrating the utility of immunosequencing from tissue and blood in predicting and monitoring response in cancer at the 2015 American Society of Clinical Oncology® (ASCO®) meeting in Chicago from May 29-June 2, 2015.

Previous publications have demonstrated the impact of cancer immunotherapies such as anti-PD1 therapy on the tumor microenvironment. New research at ASCO using the immunoSEQ® Assay will explore the effects of anti-PD1 therapy in peripheral blood. Several data sets across multiple solid tumors will be presented comparing the T-cell repertoire in the blood and in the tumor tissue, as well as in the blood alone before and after treatment, to begin to quantify and characterize response.

"As immunotherapies play an increasing important role in cancer treatment, there is a need for a new class of biomarkers that are directly linked to the dynamics of the immune system," says Dr. Harlan Robins, CSO and Co-Founder of Adaptive Biotechnologies. "Being able to accurately quantify these dynamics not only in the tissue but also in the blood may lead to a systematic way of identifying who, when and how to treat patients with immunotherapies."

Additionally, two studies will be presented showing the use of Adaptive's technology to analyze circulating tumor DNA (ctDNA) in non-Hodgkin's lymphoma, either as a pretreatment biomarker of disease burden or early on during treatment as a dynamic measure of response.

Adaptive Biotechnologies is also pleased to announce the launch of the immunoSEQ Mouse IGH assay to the immunoSEQ Service product line. The addition of the mouse IGH assay broadens Adaptive's offerings so researchers can now sequence B-cell receptors as well as T-cell receptors in mice with groundbreaking sensitivity, accuracy and specificity.  

Representatives from Adaptive Biotechnologies will be exhibiting at ASCO booth #23127 to answer questions about its immunosequencing technology.

Oral Presentations:   

Abstract No. 4500: Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): Association of biomarkers with clinical outcomes.
Presenter: Toni K. Choueiri
Oral Abstract Session: Monday, June 1, 2015, 9:45 – 12:45 p.m.
Location: E Arie Crown Theater

Abstract No. 8510: Phase II MMRC trial of extended treatment with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM).
Presenter: Todd M. Zimmerman
Oral Abstract Session: Tuesday, June 2, 2015, 9:45-12:45 p.m.
Location: E354b

Poster Presentations:

Abstract No. 609: Characterization of dominant T-cell clones by T-cell receptor (TCR) deep sequencing as a potential predictive biomarker to neoadjuvant trastuzumad (tras) in HER2-positive (HER2+) breast cancer.
Presenter: David B. Page
Poster Session: Saturday, May 30, 2015, 8:00-11:30 a.m. - Board #98
Location: S Hall A

Abstract No. 3027: TCR use and cytokine response in PD-1 blockade.
Presenter: Jesse M. Zaretsky
Poster Session: Saturday, May 30, 2015, 8:00-11:30 a.m. - Board #353
Location: S Hall A

Abstract No. 8570: Distinct early response dynamics of circulating tumor DNA and circulating tumor cells during therapy of B-cell NHL.
Presenter: David Matthew Kurtz
Poster Session: Sunday, May 31, 2015, 8:00-11:30 a.m. - Board #388 
Location: S Hall A

Abstract No. 8539: Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL).
Presenter: Florian Scherer
Poster Session:  Sunday, May 31, 2015, 8:00-11:30 a.m. - Board #356
Location: S Hall A

Abstract No. 9075: Investigation of intrapatient heterogeneity in the tumor infiltrating T cell repertoire in patients with metastatic melanoma treated with pembrolizumab.
Presenter: Rodrigo Ramella Munhoz
Poster Session: Monday, June 1, 2015, 1:15-4:45 p.m. - Board #318
Location: S Hall A

Online Only Publication:

Abstract No. e16008: Changes in circulating and intratumoral T cell clonotypes in sipuleucel-T-treated prostate cancer patients. 
Authors: Lawrence Fong, Jason Cham,

About Adaptive Biotechnologies®

Adaptive Biotechnologies is the pioneer and leader in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. Adaptive is bringing the accuracy and sensitivity of its immunosequencing platform into laboratories around the world to drive groundbreaking research in cancer and other immune-mediated diseases. Adaptive also translates immunosequencing discoveries into clinical diagnostics and therapeutic development to improve patient care.

About immunoSEQ®

Adaptive helps researchers make discoveries in oncology, autoimmune disorders and infectious diseases by offering fee-for-service access to its proprietary immune profiling sequencing technology under the immunoSEQ brand name. The immunoSEQ Kit for research use only is now available to facilitate the integration of immunosequencing into research centers. The immunoSEQ Assay is not for use in diagnostic procedures.

About clonoSEQ®

Adaptive's clonoSEQ Process enables physicians to utilize sequencing-based minimal residual disease (MRD) detection as an aid to clinical decision making for patients with lymphoid cancers (blood cancers). With its ability to detect cancer cells at a level as low as one per one million white blood cells, the clonoSEQ MRD Test is one to two orders of magnitude more sensitive than the other methods of MRD detection, such as ASO-PCR and flow cytometry. The clonoSEQ Process was previously marketed as the ClonoSIGHT™ process by Sequenta, Inc., which was acquired by Adaptive Biotechnologies in January 2015.

The company is also validating a second novel oncology diagnostic to quantify the presence and clonality of Tumor Infiltrating Lymphocytes ("TILs") and to create a reliable measure of "immunocompetency" to predict or monitor response to cancer treatments that directly alter the host immune system.

Logo -


SOURCE Adaptive Biotechnologies